Business
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profileGeorge Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a futu
About this update from Bausch Health Companies Inc.
[{"type":"image","alt":"George Medicines","displaySize":"","headline":null,"caption":"George Medicines","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/ac9086adeb02e0db25420838713379c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7BsyEtZyTwf_TZF46lhpMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ac9086adeb02e0db25420838713379c7","width":300,"height":116},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7BsyEtZyTwf_TZF46lhpMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ac9086adeb02e0db25420838713379c7","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profile","length":369,"tagName":"p"}]},{"val":[{"type":"text","content":"George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales in Brazil","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Third licensing agreement for GMRx2 follows deals with Bausch Health in Canada, Mexico, Colombia and Central America, and with Azurity Pharmaceuticals in the US ","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":737,"olType":false},{"type":"text","content":"London, UK, 2 October 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Biolab Farmacêutica (“Biolab”), one of Brazil’s largest pharmaceutical companies, granting Biolab exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Brazil.","length":416,"tagName":"p"},{"type":"text","content":"GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the t...